In this Briefing Paper LERU outlines its recommendations to improve the development of Advanced Therapy Medicinal Products (ATMPs) within the university medical centre context – for ensuring that the EU institutions, national competent authorities and other relevant bodies develop sound and workable policies which aid patient access to novel and promising therapeutic products. Essential to create improved patient access to this complex group of medicinal products’ takes collaboration, training, improving the use of the HE and increased transparency are to tackle debilitating diseases as Leukemia, Melanoma, Parkinson’s disease, Diabetes, Huntingdon’s disease, Multiple Sclerosis.
Universities play a major role in the development of ATMPs, largely because they have the necessary disease-specific expertise, capacity for innovative research and access to donor and patient material. However, universities still face challenges in bringing ATMPs to patients. At a launch event in Brussels today, LERU outlines how patient access to ATMPs can be improved at university hospital medical centres.